ASLAN CEO Carl Firth On A New Paradigm for Drug Development In Asia: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Asia continues to increase in importance for global clinical trial programs. Big pharmas such as Novartis and AstraZeneca are building up their own R&D sites while Eli Lilly and Pfizer are creating virtual R&D networks, taking advantage of the large naïve patient population and other efficiencies in Asia to accelerate drug development.